Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.75 |
| ▸ | MAOB | P27338 | 7/20 | 0.75 |
| ▸ | MAOA | P21397 | 5/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30842883 | 1.00 | PTPN1 (0.75) | PTPN1MAOBMAOAPOLBPTPN2 | |
| SCHEMBL127924 | 0.86 | PTPN1 (1.00) | PTPN1MAOBMAOAPOLBPTPN2 | |
| SCHEMBL29952282 | 0.86 | PTPN1 (1.00) | PTPN1MAOBMAOAPOLBPTPN2 | |
| SCHEMBL9618067 | 0.84 | PTPN1 (0.66) | PTPN1MAOBMAOAPOLBPTPN2 | |
| SCHEMBL2559161 | 0.80 | MAPT (0.57) | PTPN1MAOBMAOAPOLBPTGS2 | |
| SCHEMBL2559162 | 0.80 | MAPT (0.57) | PTPN1MAOBMAOAPOLBPTGS2 | |
| SCHEMBL2475452 | 0.79 | PTPN1 (0.59) | PTPN1MAOBMAOAPOLBPTPN2 | |
| SCHEMBL5149191 | 0.78 | MAOB (0.53) | PTPN1MAOBMAOAPTGS2PIM1 | |
| SCHEMBL25744219 | 0.78 | MAOB (0.53) | PTPN1MAOBMAOAPTGS2PIM1 | |
| SCHEMBL8051158 | 0.78 | MAOB (0.53) | PTPN1MAOBMAOAPTGS2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117700310-A | Synthesis method of aromatic aldehyde compound or deuterated aromatic aldehyde compound | 五邑大学 | 2024-03-15 | — | — | CN | claimed |
| CN-115232070-B | Quinolinone alkaloid derivative containing acylhydrazone group on 1-position nitrogen atom, and preparation method and application thereof | 太原理工大学 | 2023-06-30 | — | — | CN | claimed |
| CN-115232070-A | Quinolinone alkaloid derivative containing acylhydrazone group on 1-site nitrogen atom and preparation method and application thereof | 太原理工大学 | 2022-10-25 | — | — | CN | claimed |
| CN-110072859-A | Compound as ROR gamma modulators | 勃林格殷格翰国际有限公司 | 2019-07-30 | — | — | CN | claimed |
| CN-106565648-B | The synthetic method of fluorine-containing alkyl-substituted 2,3- dihydro-benzofuran derivative and indole derivatives | 华南理工大学 | 2018-12-11 | — | — | CN | claimed |
| US-20160068506-A1 | COMBRETASTATIN ANALOGS | BIOVENTURES, LLC | 2016-03-10 | — | — | US | claimed |
| EP-2986596-A2 | COMBRETASTATIN ANALOGS | The Board of Trustees of the University of Arkansas (US) | 2016-02-24 | — | — | EP | claimed |
| WO-2014172363-A2 | COMBRETASTATIN ANALOGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2014-10-23 | — | — | WO | claimed |
| CN-102822160-A | Method for preparing 3-keto-benzofurane derivatives | SANOFI AVENTIS | 2012-12-12 | — | — | CN | claimed |
| CN-101914080-B | Benzofuran-3-ketone substitute phenyl compound as well as preparation method and application | UNIV SHANGHAI JIAOTONG | 2012-10-03 | — | — | CN | claimed |
| US-7994335-B2 | Electronically tuned ligands for asymmetric hydrogenation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-09 | — | — | US | claimed |
| CN-101914080-A | Benzofuran-3-ketone substitute phenyl compound as well as preparation method and application | UNIV SHANGHAI JIAOTONG | 2010-12-15 | — | — | CN | claimed |
| US-20100041898-A1 | Electronically Tuned Ligands For Asymmetric Hydrogenation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | claimed |
| WO-2008067218-A1 | ELECTRONICALLY TUNED LIGANDS FOR ASYMMETRIC HYDROGENATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-05 | — | — | WO | claimed |
| US-6316620-B1 | AS LIGANDS TO TRANSITION METALS WHICH ARE USED AS CATALYSTS IN SYNTHESIZING ASYMMETRIC COMPOUNDS TO OBTAIN SPECIFIC ENANTIOMERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | claimed |
| US-5663168-A | ADMINISTERING INHIBITORS OF HIV ASPARATATE PROTEASES | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0626178-A1 | Use of inhibitors of HIV-protease for the treatment of tumorous diseases | CIBA-GEIGY AG (CH) | 1994-11-30 | — | — | EP | claimed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | claimed |
| EP-0532466-A2 | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | claimed |
| JP-7159818-A | — | — | None | — | — | JP | disclosed |
| CN-122059923-A | Aldehyde group-guided bi (hetero) aromatic compound and synthesis method and application thereof | 桂林理工大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-121574128-A | Pyrimidine-hydroxamic acid compounds and uses thereof | 华东理工大学 | 2026-02-27 | — | — | CN | disclosed |
| US-12454502-B2 | Synthesis of deuterated aldehydes | ARIZONA BOARD OF REGENTS ON BEHALF OF ATHE UNIVERSITY OF ARIZONA (US) | 2025-10-28 | — | — | US | disclosed |
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-115151553-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| CN-116410184-B | Quinazolinone ketene azole compound, and preparation method and application thereof | 西南大学 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025076226-A1 | FUSED HETEROCYCLES FOR TREATING NEURODEGENERATIVE DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024262824-A1 | NOVEL PROCESS FOR SYNTHESIS OF POLYSUBSTITUTED PYRIDINE DERIVATIVES | 서울대학교산학협력단 | 2024-12-26 | — | — | WO | disclosed |
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| CN-116217526-B | Aromatic heterocycle substituted alpha-methylene-gamma-butyrolactone compound, preparation method and application | 西北农林科技大学 | 2024-09-20 | — | — | CN | disclosed |
| EP-4408845-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-111491938-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024097744-A2 | DNA-COMPATIBLE WITTIG OLEFINATION OF ON-DNA PEPTIDYL-YLIDES FOR DEVELOPMENT OF ON-DNA PEPTIDOMIMETICS THROUGH DIVERSITY-ORIENTED SYNTHESIS (DOS) | THE ROCKEFELLER UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-117886774-A | Preparation method of fluoxastrobin intermediate | 江苏好收成韦恩农化股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117700310-A | Synthesis method of aromatic aldehyde compound or deuterated aromatic aldehyde compound | 五邑大学 | 2024-03-15 | — | — | CN | disclosed |
| CN-114751883-B | Preparation method of benzofuran-3-carboxamide compound | 浙江理工大学 | 2024-01-16 | — | — | CN | disclosed |
| US-11858951-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11858951-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11858951-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| CN-117305863-A | Method for electrochemically synthesizing 3-benzofuranmethanol and analogues thereof | 浙江师范大学 | 2023-12-29 | — | — | CN | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3826723-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-10-18 | — | — | EP | disclosed |
| EP-3826723-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-10-18 | — | — | EP | disclosed |
| EP-3546454-B1 | BENZOHETEROCYCLYL ALKYLAMINE COMPOUND AND USE THEREOF | UNIV EAST CHINA SCIENCE & TECH (CN) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-116410184-A | Quinazolinone ketene azole compound, and preparation method and application thereof | 西南大学 | 2023-07-11 | — | — | CN | disclosed |
| EP-3601224-B1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2023-07-05 | — | — | EP | disclosed |
| CN-115232070-B | Quinolinone alkaloid derivative containing acylhydrazone group on 1-position nitrogen atom, and preparation method and application thereof | 太原理工大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-110914238-B | Compounds as antibiotics | 安塔比奥公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-111183142-B | Boric acid derivatives | 默克专利股份公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-116217526-A | Aromatic heterocycle substituted alpha-methylene-gamma-butyrolactone compound, preparation method and application | 西北农林科技大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-115108959-B | Photobleachable visible light initiator containing benzylidene ketone structure, and preparation method and application thereof | 武汉大学 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023052783-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-04-06 | — | — | WO | disclosed |
| US-20230096978-A1 | MOR RECEPTOR AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| CN-110248949-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-112174974-B | Pyrano [3,2-b ] benzofuran-2-one framework compound and synthetic method and application thereof | 新乡学院 | 2023-02-03 | — | — | CN | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4089088-A1 | MOR RECEPTOR AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| US-20220356139-A1 | SYNTHESIS OF DEUTERATED ALDEHYDES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-11-10 | — | — | US | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232070-A | Quinolinone alkaloid derivative containing acylhydrazone group on 1-site nitrogen atom and preparation method and application thereof | 太原理工大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-115151553-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-115108959-A | Photobleachable visible light initiator containing benzylidene ketone structure and preparation method and application thereof | 武汉大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-115066428-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114956925-A | Green and efficient preparation method of aliphatic ketone | 中国人民解放军海军军医大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-114907389-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-3672977-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-20220153761-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20220153761-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| CN-109311876-B | Heteroaryl estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2022-05-03 | — | — | CN | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| US-11274109-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| US-11274109-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| CN-108239054-B | Preparation method of benzofuran-3-carboxylic acid | 上海奥博生物医药股份有限公司 | 2022-01-21 | — | — | CN | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| CN-109912576-B | Cyclic or spirocyclic diamine pyrimidine-hydroxamic acids and their use | 华东理工大学 | 2021-11-19 | — | — | CN | disclosed |
| EP-3472162-B1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210317145-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20210317145-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
| CN-109810108-B | 2, 8-diaza-spiro- [4,5] -decane pyrimidine-hydroxamic acid compound and application thereof | 华东理工大学 | 2021-08-06 | — | — | CN | disclosed |
| WO-2021143923-A1 | BORONIC ACID DERIVATIVES | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| CN-113135944-A | Boronic acid derivatives | 首药控股(北京)有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-113135943-A | Boronic acid derivatives | 首药控股(北京)有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-110156820-B | Mercaptoamide boronic acid derivatives and application thereof as MBL (sodium Bromide) and/or SBL (SBL) inhibitor | 四川大学 | 2021-06-25 | — | — | CN | disclosed |
| EP-3826723-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-11000511-B2 | Chemical compounds as antibiotics | ANTABIO SAS (FR) | 2021-05-11 | — | — | US | disclosed |
| CN-110950768-B | Photobleachable visible light initiator and preparation method and application thereof | 武汉大学 | 2021-03-16 | — | — | CN | disclosed |
| WO-2021045879-A1 | SYNTHESIS OF DEUTERATED ALDEHYDES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-3571208-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112469480-A | Boronic acid derivatives | 默克专利股份公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3201207-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-02-24 | — | — | EP | disclosed |
| CN-112174974-A | Pyrano [3,2-b ] benzofuran-2-one framework compound and synthetic method and application thereof | 新乡学院 | 2021-01-05 | — | — | CN | disclosed |
| CN-107001390-B | Boronic acid derivatives | 默克专利股份公司 | 2020-11-27 | — | — | CN | disclosed |
| CN-107001391-B | Boronic acid derivatives | 默克专利股份公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20200354382-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2020-11-12 | — | — | US | disclosed |
| US-20200354382-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2020-11-12 | — | — | US | disclosed |
| US-10829464-B2 | Benzoheterocyclic alkylamine compounds and use thereof | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2020-11-10 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3710458-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-107108660-B | Boronic acid derivatives | 默克专利股份公司 | 2020-09-15 | — | — | CN | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| CN-108084125-B | Benzoheterocyclylalkylamines and their use | 华东理工大学 | 2020-08-18 | — | — | CN | disclosed |
| CN-111491938-A | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2020-08-04 | — | — | CN | disclosed |
| EP-3672977-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10669289-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10669289-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2020-05-21 | — | — | US | disclosed |
| US-10654867-B2 | Heteroaryl estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| CN-111183142-A | Boronic acid derivatives | 默克专利股份公司 | 2020-05-19 | — | — | CN | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3201205-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-05-13 | — | — | EP | disclosed |
| EP-3201205-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-10640520-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-10640520-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| CN-110950768-A | Photobleachable visible light initiator and preparation method and application thereof | 武汉大学 | 2020-04-03 | — | — | CN | disclosed |
| CN-110914238-A | Compounds as antibiotics | 安塔比奥公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3601224-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | Antabio SAS (FR) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020020858-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020020858-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-01-30 | — | — | WO | disclosed |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-11-07 | — | — | US | disclosed |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-11-07 | — | — | US | disclosed |
| US-20190315703-A1 | BENZOHETEROCYCLIC ALKYLAMINE COMPOUNDS AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-10-17 | — | — | US | disclosed |
| EP-3546454-A1 | BENZOHETEROCYCLYL ALKYLAMINE COMPOUND AND USE THEREOF | East China University of Science and Technology (CN) | 2019-10-02 | — | — | EP | disclosed |
| EP-3201206-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-09-18 | — | — | EP | disclosed |
| CN-110248949-A | Immunoproteasome inhibitor | 普林斯匹亚生物制药公司 | 2019-09-17 | — | — | CN | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| CN-110156820-A | A kind of Mercaptoamides boric acid analog derivative and its purposes as MBL and/or SBL inhibitor | 四川大学 | 2019-08-23 | — | — | CN | disclosed |
| CN-110072859-A | Compound as ROR gamma modulators | 勃林格殷格翰国际有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-109912576-A | Cyclic annular or loop coil Diamines pyrimidine-hydroxamic acid and application thereof | 华东理工大学 | 2019-06-21 | — | — | CN | disclosed |
| CN-109810108-A | 2,8- diaza-spiro-[4,5]-decane class pyrimidine-hydroxamic acid compound and application thereof | 华东理工大学 | 2019-05-28 | — | — | CN | disclosed |
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | MERCK PATENT GMBH (DE) | 2019-05-21 | — | — | US | disclosed |
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | MERCK PATENT GMBH (DE) | 2019-05-21 | — | — | US | disclosed |
| EP-3472162-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| CN-109651313-A | A kind of chirality 2,3- dihydro-benzofuran derivative and preparation method thereof | 四川大学 | 2019-04-19 | — | — | CN | disclosed |
| WO-2019038250-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | disclosed |
| CN-109311876-A | heteroaryl estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-106565648-B | The synthetic method of fluorine-containing alkyl-substituted 2,3- dihydro-benzofuran derivative and indole derivatives | 华南理工大学 | 2018-12-11 | — | — | CN | disclosed |
| US-10100029-B2 | Combretastatin analogs | BIOVENTURES, LLC (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018172423-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2018-09-27 | — | — | WO | disclosed |
| EP-2793900-B1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING SA (CH) | 2018-08-22 | — | — | EP | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| CN-104321060-B | Alpha-amino boronic acid derivative, selective immunoproteasome inhibitor | 阿雷斯贸易股份有限公司 | 2018-08-07 | — | — | CN | disclosed |
| CN-105189486-B | Conjugate of benzofuranone and indole or azaindole, preparation and application thereof | 滁州市洛达生物科技有限公司 | 2018-07-31 | — | — | CN | disclosed |
| WO-2018136401-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| CN-108239054-A | A kind of preparation method of benzofuran -3- carboxylic acids | 上海奥博生物医药技术有限公司 | 2018-07-03 | — | — | CN | disclosed |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180118710-A1 | COMBRETASTATIN ANALOGS | BIOVENTURES, LLC | 2018-05-03 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180105539-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105539-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105539-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-04-19 | — | — | US | disclosed |
| CN-107690428-A | process for the preparation of (E) - (5, 6-dihydro-1, 4, 2-dioxazin-3-yl) (2-hydroxyphenyl) methanone O-methyloxime | 爱利思达生命科学株式会社 | 2018-02-13 | — | — | CN | disclosed |
| US-9884842-B2 | Combretastatin analogs | BIOVENTURES, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| CN-104363879-B | cosmetic composition comprising composite particles | 莱雅公司 | 2018-01-30 | — | — | CN | disclosed |
| CN-107602513-A | Aurones analog derivative, its preparation method and medical usage | 中国药科大学 | 2018-01-19 | — | — | CN | disclosed |
| US-20180002344-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| CN-105859737-B | Natural flavone Anastatin B derivative and preparation and application | 天津科技大学 | 2017-12-26 | — | — | CN | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9789120-B2 | Male contraceptive compositions and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789120-B2 | Male contraceptive compositions and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| CN-107108660-A | Boronic acid derivatives | 默克专利股份公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-3201205-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2017-08-09 | — | — | EP | disclosed |
| EP-3201207-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2017-08-09 | — | — | EP | disclosed |
| EP-3201206-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2017-08-09 | — | — | EP | disclosed |
| CN-107001391-A | Boronic acid derivatives | 默克专利股份公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-107001390-A | Boronic acid derivatives | 默克专利股份公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-106986865-A | On Mental disease or the compound and medical composition of malignant tumour | 国立大学法人京都大学 | 2017-07-28 | — | — | CN | disclosed |
| CN-105263902-B | The improved method for preparing specific oxime and oxime ether | 拜耳作物科学股份公司 | 2017-07-25 | — | — | CN | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| CN-106565648-A | Synthetic method of fluorine-containing alkyl substituted 2,3-dihydrocoumarone derivatives and indole derivatives | 华南理工大学 | 2017-04-19 | — | — | CN | disclosed |
| CN-104520303-B | Compound and pharmaceutical composition for mental and neurological diseases or malignant tumors | 国立大学法人京都大学 | 2017-04-12 | — | — | CN | disclosed |
| CN-106458926-A | Pyridazinone herbicides | 杜邦公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170029437-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH- DIRECTOR DEITR | 2017-02-02 | — | — | US | disclosed |
| US-20170029437-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH- DIRECTOR DEITR | 2017-02-02 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| CN-105859737-A | Derivative of natural flavone anastatin B as well as preparation and application thereof | 天津科技大学 | 2016-08-17 | — | — | CN | disclosed |
| US-9320741-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9320741-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2016050355-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050358-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050359-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | disclosed |
| US-9301962-B2 | Male contraceptive compositions and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301962-B2 | Male contraceptive compositions and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160068506-A1 | COMBRETASTATIN ANALOGS | BIOVENTURES, LLC | 2016-03-10 | — | — | US | disclosed |
| EP-2986596-A2 | COMBRETASTATIN ANALOGS | The Board of Trustees of the University of Arkansas (US) | 2016-02-24 | — | — | EP | disclosed |
| CN-105189486-A | Conjugate of benzofuranone and indole or azaindole, preparation and application thereof | LUODA BIOSCIENCES INC | 2015-12-23 | — | — | CN | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| CN-103333161-B | The preparation of 1 '-oxo Indirubin and purposes | LUODA BIOSCIENCES INC. (CN) | 2015-09-30 | — | — | CN | disclosed |
| CN-103333161-B | The preparation of 1 '-oxo Indirubin and purposes | LUODA BIOSCIENCES INC. (CN) | 2015-09-30 | — | — | CN | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-8981083-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA FARBER CANCER INSTITUTE, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981083-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA FARBER CANCER INSTITUTE, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| CN-104363879-A | Cosmetic composition comprising composite particles | OREAL | 2015-02-18 | — | — | CN | disclosed |
| CN-104321060-A | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA | 2015-01-28 | — | — | CN | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| EP-2793900-A1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | Ares Trading S.A. (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014172363-A2 | COMBRETASTATIN ANALOGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| CN-103333161-A | Preparation method and use of 1'-oxo-indirubin | UNIV CHINA PHARMA | 2013-10-02 | — | — | CN | disclosed |
| CN-103333161-A | Preparation method and use of 1'-oxo-indirubin | UNIV CHINA PHARMA | 2013-10-02 | — | — | CN | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| CN-102190661-B | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD | 2013-07-31 | — | — | CN | disclosed |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| WO-2013092979-A1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING S.A. (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092979-A1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING S.A. (CH) | 2013-06-27 | — | — | WO | disclosed |
| CN-102988371-A | Kidney-warming and cold-dissipating tablet | JIANGSU LAOCANFANG SILKWORM BIO TECHNOLOGY & DEV CO LTD | 2013-03-27 | — | — | CN | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120323002-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2012-12-20 | — | — | US | disclosed |
| CN-102822160-A | Method for preparing 3-keto-benzofurane derivatives | SANOFI AVENTIS | 2012-12-12 | — | — | CN | disclosed |
| US-8314098-B2 | Pyrazolo-pyrimidine compounds | AJINOMOTO CO., INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| EP-2518072-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2012-10-31 | — | — | EP | disclosed |
| CN-1934116-B | Tricyclic benzopyran compounds useful as antiarrhythmic agents | NISSAN CHEMICAL IND LTD | 2012-10-10 | — | — | CN | disclosed |
| CN-101914080-B | Benzofuran-3-ketone substitute phenyl compound as well as preparation method and application | UNIV SHANGHAI JIAOTONG | 2012-10-03 | — | — | CN | disclosed |
| CN-101914080-B | Benzofuran-3-ketone substitute phenyl compound as well as preparation method and application | UNIV SHANGHAI JIAOTONG | 2012-10-03 | — | — | CN | disclosed |
| CN-101914080-B | Benzofuran-3-ketone substitute phenyl compound as well as preparation method and application | UNIV SHANGHAI JIAOTONG | 2012-10-03 | — | — | CN | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| CN-101437827-B | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL IND LTD | 2012-08-29 | — | — | CN | disclosed |
| WO-2012110833-A2 | FLUORESCENCE MODULATORS | ALMAC SCIENCES (SCOTLAND) LIMITED (GB) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012110833-A2 | FLUORESCENCE MODULATORS | ALMAC SCIENCES (SCOTLAND) LIMITED (GB) | 2012-08-23 | — | — | WO | disclosed |
| US-8212049-B2 | Electronically tuned ligands for asymmetric hydrogenation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| CN-101429200-B | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD | 2012-05-30 | — | — | CN | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101060838-B | Novel tetracyclic heteroatom containing derivatives as modulators of steroid sex hormone receptors | JANSSEN PHARMACEUTICA NV | 2012-02-29 | — | — | CN | disclosed |
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20110257393-A1 | Electronically Tuned Ligands For Asymmetric Hydrogenation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| CN-102190661-A | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD | 2011-09-21 | — | — | CN | disclosed |
| US-7994335-B2 | Electronically tuned ligands for asymmetric hydrogenation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2319841-A1 | (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE | MSD K.K. (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2319841-A1 | (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE | MSD K.K. (JP) | 2011-05-11 | — | — | EP | disclosed |
| CN-101068810-B | Carbostyril compound | OTSUKA PHARMA CO LTD | 2011-02-09 | — | — | CN | disclosed |
| CN-101914080-A | Benzofuran-3-ketone substitute phenyl compound as well as preparation method and application | UNIV SHANGHAI JIAOTONG | 2010-12-15 | — | — | CN | disclosed |
| CN-101914080-A | Benzofuran-3-ketone substitute phenyl compound as well as preparation method and application | UNIV SHANGHAI JIAOTONG | 2010-12-15 | — | — | CN | disclosed |
| CN-101914080-A | Benzofuran-3-ketone substitute phenyl compound as well as preparation method and application | UNIV SHANGHAI JIAOTONG | 2010-12-15 | — | — | CN | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100041898-A1 | Electronically Tuned Ligands For Asymmetric Hydrogenation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-7659267-B2 | 1,3-Benzothiazinone derivatives, process for producing the same use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-09 | — | — | US | disclosed |
| WO-2010013595-A1 | (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE | 萬有製薬株式会社 (JP) | 2010-02-04 | — | — | WO | disclosed |
| CN-101636392-A | Process for production of optically active epoxy compound | NISSAN CHEMICAL IND LTD | 2010-01-27 | — | — | CN | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-2133343-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| WO-2009085256-A1 | ANTI-HIV COMPOUNDS | PANACOS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085256-A1 | ANTI-HIV COMPOUNDS | PANACOS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| CN-101437827-A | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL IND LTD (JP) | 2009-05-20 | — | — | CN | disclosed |
| CN-101429200-A | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-2042491-A1 | Pyridazines as fungicides | Bayer CropScience AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008067218-A1 | ELECTRONICALLY TUNED LIGANDS FOR ASYMMETRIC HYDROGENATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1495009-B1 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-101068810-A | Carbostyril compound | OTSUKA PHARMA CO LTD (JP) | 2007-11-07 | — | — | CN | disclosed |
| CN-101060838-A | Novel tetracyclic heteroatom containing derivatives as modulators of steroid sex hormone receptors | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-24 | — | — | CN | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| CN-1934116-A | Tricyclic benzopyran compounds useful as antiarrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| EP-1578740-A1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. Lundbeck A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| EP-1568697-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| CN-1658873-A | New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658834-A | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | disclosed |
| WO-2004058739-A1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. LUNDBECK A/S (DK) | 2004-07-15 | — | — | WO | disclosed |
| US-6753449-B2 | ALLYL-5-AMINOPENTANOIC ACID/2-/ COVALENTLY ATTACHED TO AN AGAROSE OR POLYSTYRENE SOLID SUPPORTS; USE FOR BUILDING PHARMACEUTICAL DRUGS COLLECTIONS LIBRARIES | ARQULE, INC. | 2004-06-22 | — | — | US | disclosed |
| JP-2004091426-A | METHOD FOR PRODUCING ACETOPHENONE DERIVATIVE | TANABE SEIYAKU CO LTD | 2004-03-25 | — | — | JP | disclosed |
| EP-1218388-B1 | ELECTRONICALLY TUNED LIGANDS | BOEHRINGER INGELHEIM PHARMA (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003086325-A2 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030096301-A1 | Linker for solid-phase synthesis | ARQULE, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030065007-A1 | NK1 receptor antagonists | CRESWELL MARK WALLACE (US) | 2003-04-03 | — | — | US | disclosed |
| US-6472418-B1 | Non-peptide NK1 receptors antagonists | WARNER-LAMBERT COMPANY | 2002-10-29 | — | — | US | disclosed |
| EP-1218388-A1 | ELECTRONICALLY TUNED LIGANDS | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| JP-2002155077-A | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, BENZOFURAN-CYCLIC HYDRAZONE COMPOUND USEFUL FOR THE SAME AND METHOD FOR MANUFACTURING THE SAME | SHARP CORP | 2002-05-28 | — | — | JP | disclosed |
| JP-2002123013-A | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, BENZOFURAN STYRYL COMPOUND TO BE USED FOR THE SAME, AND METHOD FOR MANUFACTURING THE SAME | SHARP CORP | 2002-04-26 | — | — | JP | disclosed |
| JP-2002091035-A | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, BENZOFURAN- HYDRAZONE COMPOUND AND ITS INTERMEDIATE TO BE USED FOR THE SAME AND METHOD FOR MANUFACTURING THE SAME | SHARP CORP | 2002-03-27 | — | — | JP | disclosed |
| US-6316620-B1 | AS LIGANDS TO TRANSITION METALS WHICH ARE USED AS CATALYSTS IN SYNTHESIZING ASYMMETRIC COMPOUNDS TO OBTAIN SPECIFIC ENANTIOMERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1140914-A1 | NON-PEPTIDE NK1 RECEPTORS ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001018012-A1 | ELECTRONICALLY TUNED LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000037462-A1 | NON-PEPTIDE NK1 RECEPTORS ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |
| US-5663168-A | ADMINISTERING INHIBITORS OF HIV ASPARATATE PROTEASES | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5643878-A | TREATMENT OF RETROVIRAL DISEASES LIKE AIDS | CIBA-GEIGY CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| JP-H07159818-A | MOLECULAR CRYSTAL AND LIGHT CONTROLLING METHOD USING THE SAME | SUMITOMO ELECTRIC IND LTD | 1995-06-23 | — | — | JP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0626178-A1 | Use of inhibitors of HIV-protease for the treatment of tumorous diseases | CIBA-GEIGY AG (CH) | 1994-11-30 | — | — | EP | disclosed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0532466-A2 | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| CN-1062139-A | Process for preparing phenoxypyrimidine compounds | ICI PLC (GB) | 1992-06-24 | — | — | CN | disclosed |
| US-4948893-A | RESONANT DYE CHROMOGENS | EASTMAN KODAK COMPANY (US) | 1990-08-14 | — | — | US | disclosed |
| US-4000281-A | VIRICIDES | RICHARDSON-MERRELL INC. (US) | 1976-12-28 | — | — | US | disclosed |
| US-4000281-A | VIRICIDES | RICHARDSON-MERRELL INC. (US) | 1976-12-28 | — | — | US | disclosed |
| US-4000281-A | VIRICIDES | RICHARDSON-MERRELL INC. (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | PTPN1 2950/4885MAOB 1658/4885MAOA 2017/4885 |
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | SHBG, CYP19A1, CYP17A1 | PTPN1 2102/4885MAOB 820/4885MAOA 750/4885 |
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | IL23R, IL2, IL17A | PTPN1 701/4885MAOB 3979/4885MAOA 3745/4885 |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | OSTC, EEF1D, SQLE | PTPN1 3661/4885MAOB 459/4885MAOA 214/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | PTPN1 2390/4885MAOB 4207/4885MAOA 4253/4885 |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | PTPN1 2390/4885MAOB 4207/4885MAOA 4253/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | PTPN1 721/4885MAOB 3807/4885MAOA 4049/4885 |
| US-10669289-B2 | Boronic acid derivatives | BCL9, BCL9L, BCL6 | PTPN1 491/4885MAOB 3416/4885MAOA 4192/4885 |
| US-20180105539-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | PTPN1 491/4885MAOB 3416/4885MAOA 4192/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | PTPN1 3412/4885MAOB 4047/4885MAOA 4200/4885 |
| US-20210317145-A1 | Boronic Acid Derivatives | PSMB7, PSMA7, BRD7 | PTPN1 2194/4885MAOB 2949/4885MAOA 3607/4885 |
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | MCHR1, MC5R, MCHR2 | PTPN1 2136/4885MAOB 95/4885MAOA 141/4885 |
| US-20100041898-A1 | Electronically Tuned Ligands For Asymmetric Hydrogenation | BID, HDHD5, HRH4 | PTPN1 4520/4885MAOB 2480/4885MAOA 2667/4885 |
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | PTPN1 491/4885MAOB 3416/4885MAOA 4192/4885 |
| US-20220153761-A1 | Boronic Acid Derivatives | PSMB7, PSMA7, BRD7 | PTPN1 2012/4885MAOB 3165/4885MAOA 3942/4885 |
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | PTPN1 1236/4885MAOB 2043/4885MAOA 4200/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | PTPN1 2390/4885MAOB 4207/4885MAOA 4253/4885 |
| US-12454502-B2 | Synthesis of deuterated aldehydes | ADH1C, ADH1A, CBR1 | PTPN1 4604/4885MAOB 404/4885MAOA 436/4885 |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | MRPL21, CFTR, H1-0 | PTPN1 121/4885MAOB 2404/4885MAOA 2228/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | PTPN1 924/4885MAOB 2792/4885MAOA 3677/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | PTPN1 2102/4885MAOB 820/4885MAOA 750/4885 |
| US-10829464-B2 | Benzoheterocyclic alkylamine compounds and use thereof | AADAC, AAAS, NISCH | PTPN1 4351/4885MAOB 370/4885MAOA 307/4885 |
| US-20030065007-A1 | NK1 receptor antagonists | HRH1, HRH4, HRH2 | PTPN1 1185/4885MAOB 2256/4885MAOA 1981/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | PTPN1 2390/4885MAOB 4207/4885MAOA 4253/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | PTPN1 721/4885MAOB 3807/4885MAOA 4049/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | PTPN1 924/4885MAOB 2792/4885MAOA 3677/4885 |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | MCL1, ABL1, FLT3 | PTPN1 924/4885MAOB 2792/4885MAOA 3677/4885 |
| US-11154563-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | PTPN1 2313/4885MAOB 4285/4885MAOA 4316/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | PTPN1 1691/4885MAOB 4538/4885MAOA 4581/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | PTPN1 2390/4885MAOB 4207/4885MAOA 4253/4885 |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | PTPN1 491/4885MAOB 3416/4885MAOA 4192/4885 |
| US-10640520-B2 | Boronic acid derivatives | BCL9, BCL9L, BCL6 | PTPN1 491/4885MAOB 3416/4885MAOA 4192/4885 |
| US-20180002344-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESRRA | PTPN1 1471/4885MAOB 1011/4885MAOA 797/4885 |
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | PSMB7, PSMA7, PSMB11 | PTPN1 1272/4885MAOB 2500/4885MAOA 3594/4885 |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | PTPN1 2851/4885MAOB 214/4885MAOA 102/4885 |
| US-20120323002-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | IL23R, IL15, IL5 | PTPN1 648/4885MAOB 3088/4885MAOA 1975/4885 |
| US-20180118710-A1 | COMBRETASTATIN ANALOGS | HDAC6, HDAC11, HDAC5 | PTPN1 4492/4885MAOB 2575/4885MAOA 3307/4885 |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | PTPN1 2313/4885MAOB 4285/4885MAOA 4316/4885 |
| US-20110257393-A1 | Electronically Tuned Ligands For Asymmetric Hydrogenation | BID, HDHD5, HRH4 | PTPN1 4520/4885MAOB 2480/4885MAOA 2667/4885 |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | BRPF3, EP300, BRD3 | PTPN1 3412/4885MAOB 4047/4885MAOA 4200/4885 |
| US-11000511-B2 | Chemical compounds as antibiotics | MRPL21, CFTR, H1-0 | PTPN1 121/4885MAOB 2404/4885MAOA 2228/4885 |
| US-10100029-B2 | Combretastatin analogs | HDAC6, HDAC11, HDAC5 | PTPN1 4492/4885MAOB 2575/4885MAOA 3307/4885 |
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | PTPN1 857/4885MAOB 3011/4885MAOA 3306/4885 |
| US-20230096978-A1 | MOR RECEPTOR AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | OPRM1, OPRL1, OPRD1 | PTPN1 4648/4885MAOB 1882/4885MAOA 1521/4885 |
| US-11274109-B2 | Boronic acid derivatives | PSMB7, PSMA7, BRD7 | PTPN1 2011/4885MAOB 3113/4885MAOA 3929/4885 |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | PSMB7, PSMA7, PSMB1 | PTPN1 1720/4885MAOB 3078/4885MAOA 3996/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | PTPN1 1691/4885MAOB 4538/4885MAOA 4581/4885 |
| US-20190315703-A1 | BENZOHETEROCYCLIC ALKYLAMINE COMPOUNDS AND USE THEREOF | AADAC, AAAS, NISCH | PTPN1 4351/4885MAOB 370/4885MAOA 307/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | PTPN1 3160/4885MAOB 1824/4885MAOA 2329/4885 |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | BRPF3, EP300, BRD3 | PTPN1 3412/4885MAOB 4047/4885MAOA 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.